Xbiotech Inc (XBIT) Stock Price, Quote & News

Latest News on XBIT

Mar 2, 2025, 11:00 AM EST - 7 weeks ago

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

Feb 2, 2025, 11:00 AM EST - 2 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into XBiotech Inc. For Securities Fraud

Jan 29, 2025, 10:00 AM EST - 3 months ago

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jan 28, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Shareholders to Inquire about Securities Investigation

Jan 27, 2025, 11:15 AM EST - 3 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into XBiotech Inc. For Securities Fraud

Jan 27, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Shareholders to Connect

Jan 26, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Shareholders to Reach Out

Jan 24, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Investors to Learn More About the Investigation

Jan 23, 2025, 10:00 AM EST - 3 months ago

XBiotech Inc. (XBIT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 22, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Investors to Connect

Jan 21, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Stockholders to Inquire about Securities Investigation

Jan 19, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against XBiotech Inc. (XBIT) and Encourages Stockholders to Learn More About the Investigation

Jan 17, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages XBiotech Inc. (XBIT) Investors to Inquire about Securities Investigation

Jan 17, 2025, 5:19 AM EST - 3 months ago

XBIT Investors Have Opportunity to Join XBiotech Inc. Fraud Investigation with the Schall Law Firm

Jan 16, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Investors to Reach Out

Jan 15, 2025, 11:15 AM EST - 3 months ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into XBiotech Inc For Securities Fraud

Jan 15, 2025, 10:00 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against XBiotech Inc. (XBIT) And Encourages Stockholders to Reach Out

Jan 14, 2025, 4:37 PM EST - 3 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating XBiotech for potential violations of securities laws

Jan 14, 2025, 11:15 AM EST - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating XBiotech Inc. (XBIT) And Encourages Stockholders to Connect

Jan 13, 2025, 9:15 PM EST - 3 months ago

The Schall Law Firm Urges Shareholders With Losses To Join A Securities Fraud Inquiry Into XBiotech Inc.

Dec 23, 2024, 9:00 AM EST - 4 months ago

XBiotech Pauses Rheumatology program

Jun 18, 2024, 1:08 PM EDT - 11 months ago

What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday?

Jun 18, 2024, 11:35 AM EDT - 11 months ago

XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

May 24, 2024, 4:08 PM EDT - 11 months ago

XBiotech: Several Shots On Goal In Big Target Market Indications

Jan 4, 2024, 9:00 AM EST - 1 year ago

XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus

Nov 14, 2023, 9:00 AM EST - 1 year ago

Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis

Sep 26, 2023, 9:00 AM EDT - 1 year ago

XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke

Aug 30, 2023, 9:00 AM EDT - 1 year ago

XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer

Aug 8, 2023, 11:47 AM EDT - 1 year ago

Market Cap	95.12M
Revenue (ttm)	0.00
Net Income (ttm)	-38.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.06

Volume	49,500
Avg Vol	51,648
Day's Range	N/A - N/A
Shares Out	30.49M
Stochastic %K	62%
Beta	1.28
Analysts	Strong Buy
Price Target	$18.00